Loading...
Vaccine Vectors Harnessing the Power of Cytomegaloviruses.
Ynga-Durand, Mario Alberto Dekhtiarenko, Iryna Cicin-Sain, Luka
Ynga-Durand, Mario Alberto
Dekhtiarenko, Iryna
Cicin-Sain, Luka
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-10-17
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 2.24 MB
Other Titles
Abstract
Cytomegalovirus (CMV) species have been gaining attention as experimental vaccine vectors inducing cellular immune responses of unparalleled strength and protection. This review outline the strengths and the restrictions of CMV-based vectors, in light of the known aspects of CMV infection, pathogenicity and immunity. We discuss aspects to be considered when optimizing CMV based vaccines, including the innate immune response, the adaptive humoral immunity and the T-cell responses. We also discuss the antigenic epitopes presented by unconventional major histocompatibility complex (MHC) molecules in some CMV delivery systems and considerations about routes for delivery for the induction of systemic or mucosal immune responses. With the first clinical trials initiating, CMV-based vaccine vectors are entering a mature phase of development. This impetus needs to be maintained by scientific advances that feed the progress of this technological platform.
Citation
Vaccines (Basel). 2019 Oct 17;7(4). pii: vaccines7040152. doi: 10.3390/vaccines7040152.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
2076-393X
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International